Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts
30 mars 2022 16h01 HE
|
Crinetics Pharmaceuticals, Inc.
Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call...
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
08 mai 2020 09h01 HE
|
Crinetics Pharmaceuticals, Inc.
Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly Completed successful public offering raising net proceeds of $107.9 million ...
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
15 avr. 2020 00h21 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
09 mars 2020 16h10 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
19 févr. 2020 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
10 févr. 2020 08h30 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical...
Rezolute to Present at BIO CEO & Investor Conference 2020
27 janv. 2020 08h30 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical...
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
02 janv. 2019 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference
20 nov. 2018 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
13 nov. 2018 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...